Unraveling mitochondrial pyruvate dysfunction to mitigate hyperlactatemia and lethality in sepsis.

Summary

In a CLP mouse model, sepsis nearly abolishes mitochondrial pyruvate-driven respiration due to pyruvate dehydrogenase complex failure caused by thiamine pyrophosphate depletion. TPP supplementation restores pyruvate oxidation, reduces hyperlactatemia, enables safe glucose administration, and improves survival.

Key Findings

• Sepsis abolishes mitochondrial pyruvate-driven respiration without defects in pyruvate uptake or carboxylation, implicating PDC dysfunction.
• PDC failure is driven by thiamine pyrophosphate shortage rather than enzyme inactivation.
• TPP supplementation restores pyruvate oxidation, reduces hyperlactatemia, allows safe glucose administration, and improves survival in mice.

Clinical Implications

Consider early thiamine (TPP precursor) assessment/supplementation in septic patients with hyperlactatemia while definitive trials are conducted; findings rationalize ongoing interest in thiamine for lactate control.

Limitations

• Preclinical mouse study; human dosing, timing, and heterogeneity remain untested.
• Liver-focused mechanisms may not capture organ-specific variability in human sepsis.

Future Directions

Conduct early-phase clinical trials testing thiamine/TPP-guided resuscitation targeting hyperlactatemia; assess biomarker-driven selection and organ-specific metabolic phenotypes.